<DOC>
	<DOCNO>NCT01562210</DOCNO>
	<brief_summary>Phase I dose escalate trial . Primary objective study define maximal tolerate dose ( MTD ) Olaparib combination high dose radiotherapy without daily dose Cisplatin locally advance NSCLC . Secondary objective include define safety profile , determine PK/Pd variable document preliminary evidence objective tumor response .</brief_summary>
	<brief_title>Olaparib Dose Escalating Trial + Concurrent RT With Without Cisplatin Locally Advanced NSCLC</brief_title>
	<detailed_description>Concurrent chemoradiotherapy ( CCRT ) treatment choice patient locally advanced NSCLC . The cure rate however need improve . The main mechanism radiation Cisplatin kill tumor cell accumulation un- misrepaired DNA damage.PARP inhibitor increase radiation chemotherapy ( Cisplatin ) response preclinical study include lung cancer model . This open label dose escalate trial consist screen phase , treatment phase follow phase . The screening phase : patient tolerate concurrent cisplatin receive Olaparib , RT Cisplatin . Patients tolerate concurrent cisplatin receive Olaparib RT without prior sequential chemotherapy . The treatment phase : dose escalation Olaparib perform cohort 3 subject . The decision escalate next dose level base occurrence DLTs DLT evaluation period ( i.e . 3 month follow last day irradiation ) make patient within cohort complete third month follow . Active follow-up phase : frequent follow take place first 3 month ( acute toxicity ) . Thereafter patient monitor late toxicity disease activity 3-monthly throughout first year thereafter 6-monthly 5 year , patient deem cured follow longer warrant . Olaparib give orally BID 36 consecutive day , administrate 12 hour interval . Olaparib start 2 day start RT continue 2 day last RT fraction . Olaparib also give non-radiotherapy day maintenance treatment give radiotherapy finish . Radiotherapy ( patient ) : total dose 66Gy give 24 fraction week 1 5 . Cisplatin ( concurrent chemoradiotherapy ) : daily dose Cisplatin 6mg/m2 ( 5 days/week ) , 1-1.5 hr irradiation ( week 1 5 ) , give 5-minutes intravenous infusion .</detailed_description>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>≥18 year age Histologically cytologically confirm diagnosis NSCLC Stage II/III nonoperable disease , without malignant pleural effusion Presence least one measurable target lesion Acceptable pulmonary function define Fev1 ≥30 % DLCO ≥ 40 % predict , NYHA III functional status Expected risk radiationinduced pulmonary toxicity modest : MLD ≤ 20 maximum cord dose 50 Gy WHO performance 01 Life expectancy least 6 month Adequate hematological , renal hepatic function Hemoglobin ≥ 5.5 mmol/l Leucocytes &gt; 3.0 x 109/l Absolute neutrophil count &gt; 1.5x109/l Platelet count &gt; 100 x 109/l Total bilirubin &lt; 1.5 x UNL ASAT/ALAT &lt; 2.5 x UNL Alkaline phosphatase &lt; 5 x UNL Creatinine &lt; 130 mmol/l creatinine clearance &gt; 50 ml/min ; measure calculate Urine dipstick proteinuria &lt; 2+ . If urine dipstick ≥ 2 , 24 hour urine must demonstrate &lt; 500 mg protein 24 hour No preexist sensory neurotoxicity grade ≥ 1 ( CTCAE ) Patients reproductive potential must agree practice two effective medically approve contraceptive method trial 3 month afterwards Signed write informed consent . Concurrent active malignancy localize , nonmelanoma skin cancer carcinomainsitu cervix ( unless definitive treatment complete 5 year study entry patient remain disease free ) Anticancer therapy include chemotherapy , radiotherapy , endocrine therapy , immunotherapy use investigational agent within 3 week prior start therapy ( long period depend defined characteristic agent use e.g . 6 week mitomycin nitrosourea ) . Patients may continue use LHRH agonist cancer ; bisphosphonates bone disease corticosteroid . Patients , select sequential chemoradiotherapy , exclude disease control ( response except progression ) obtain induction chemotherapy . Prior : Ipsilateral radiotherapy chest ; Chemotherapy indication NSCLC within last 5 year History interstitial pneumonitis ( include diffuse alveolar damage , nonmalignant cause pneumonitis , ARDS , alveolitis , cryptogenic organise pneumonia , obliterative bronchiolitis , nonmalignant cause pulmonary fibrosis , eligibility base judgement primary investigator ) , active infection day enrolment Significant cardiovascular disease define : History congestive heart failure require therapy ; History unstable angina pectoris myocardial infarction 6 month prior trial entry ; Presence severe valvular heart disease ; Presence ventricular arrhythmia require treatment ; Uncontrolled hypertension Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition assess patient registration trial . Participation trial investigational drug treatment modality Coexisting serious active infection require parenteral antibiotic Patients hepatic disease e.g . patient know serologically positive Hepatitis B Hepatitis C may risk toxicity Olaparib Immunocompromised patient e.g . human immunodeficiency virus ( HIV ) Myelodysplastic syndrome/acute myeloid leukaemia feature suggestive MDS/AML peripheral blood smear . Any coexist medical condition investigator 's judgement substantially increase risk associate patient 's participation study Gastrointestinal disorder may interfere absorption study drug patient able take oral medication Concomitant medication : Any previous treatment PARP inhibitor , include Olaparib Patients receive follow class inhibitor CYP3A4 ( see Section 7.4 guideline wash period ) Azole antifungal Macrolide antibiotic Protease inhibitor Persistent grade 2 great toxicity , cause Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Olaparib</keyword>
	<keyword>CCRT</keyword>
</DOC>